Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.
BMC Cancer. 2023 Oct 25;23(1):1032. doi: 10.1186/s12885-023-11549-z.
BMC Cancer. 2023.
PMID: 37875869
Free PMC article.
Clinical Trial.
Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
Tulyte S, Characiejus D, Matuzeviciene R, Janiulioniene A, Radzevicius M, Jasiunaite E, Zvirblis T, Sileikis A.
Tulyte S, et al.
Int Immunopharmacol. 2023 Feb;115:109722. doi: 10.1016/j.intimp.2023.109722. Epub 2023 Jan 20.
Int Immunopharmacol. 2023.
PMID: 37724957
Free article.
Item in Clipboard
Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study.
Cesas A, Urbonas V, Tulyte S, Janciauskiene R, Liutkauskiene S, Grabauskyte I, Gaidamavicius I.
Cesas A, et al. Among authors: tulyte s.
J Cancer Res Clin Oncol. 2023 Aug;149(10):6979-6988. doi: 10.1007/s00432-023-04645-x. Epub 2023 Feb 27.
J Cancer Res Clin Oncol. 2023.
PMID: 36847839
Free PMC article.
Item in Clipboard
The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC).
Tulyte S, Characiejus D, Matuzeviciene R, Janiulioniene A, Radzevicius M, Zvirblis T, Sileikis A.
Tulyte S, et al.
Anticancer Res. 2022 Jun;42(6):3067-3073. doi: 10.21873/anticanres.15794.
Anticancer Res. 2022.
PMID: 35641268
Item in Clipboard
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators.
Vogelzang NJ, et al.
JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298.
JAMA Oncol. 2022.
PMID: 35142815
Free PMC article.
Clinical Trial.
Item in Clipboard
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, Ascierto PA, Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B.
Atkinson VG, et al. Among authors: tulyte s.
Cancers (Basel). 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466.
Cancers (Basel). 2021.
PMID: 34070224
Free PMC article.
Item in Clipboard
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV.
Atkinson V, et al. Among authors: tulyte s.
Melanoma Res. 2020 Jun;30(3):261-267. doi: 10.1097/CMR.0000000000000654.
Melanoma Res. 2020.
PMID: 31895752
Item in Clipboard
Cite
Cite